8.62
전일 마감가:
$8.23
열려 있는:
$8.23
하루 거래량:
870.98K
Relative Volume:
0.77
시가총액:
$494.31M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.6388
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+0.94%
1개월 성능:
-16.71%
6개월 성능:
+9.67%
1년 성능:
-19.81%
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
8.62 | 494.31M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
2025-02-07 | 재개 | Raymond James | Outperform |
2024-11-15 | 재개 | Morgan Stanley | Overweight |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-06-07 | 개시 | Goldman | Buy |
2024-03-11 | 개시 | H.C. Wainwright | Buy |
2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-02-21 | 재개 | Raymond James | Outperform |
2023-11-01 | 개시 | Stifel | Buy |
2023-06-02 | 개시 | Robert W. Baird | Outperform |
2022-06-23 | 개시 | Berenberg | Buy |
2021-12-15 | 개시 | Wedbush | Neutral |
2021-10-19 | 재개 | Morgan Stanley | Overweight |
2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2020-12-16 | 개시 | UBS | Buy |
2020-06-25 | 재개 | BofA/Merrill | Buy |
2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
2019-06-14 | 재개 | Raymond James | Outperform |
2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
2018-11-08 | 재확인 | BofA/Merrill | Neutral |
2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
2018-05-09 | 재확인 | Barclays | Overweight |
2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2018-02-13 | 개시 | Mizuho | Neutral |
2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - MarketScreener
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive
RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter
REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa
Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech
New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com
Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia
REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview
Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg
Transcript : REGENXBIO Inc.Special Call - MarketScreener
Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus
Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News - GuruFocus
REGENXBIO reports progress in Duchenne treatment trial - Investing.com Australia
REGENXBIO stock in focus after data for Duchenne drug (RGNX) - Seeking Alpha
Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202 - MarketScreener
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II A - GuruFocus
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | RGNX Stock News - GuruFocus
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire
RegenXBio Holds 2025 Annual Stockholders Meeting - TipRanks
ProShare Advisors LLC Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - Eagle-Tribune
REGENXBIO to Host Webcast Discussing Interim Functional Data fro - GuruFocus
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 | RGNX Stock News - GuruFocus
Leerink Partnrs Weighs in on REGENXBIO FY2026 Earnings - Defense World
Ameriprise Financial Inc. Has $2.20 Million Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $775,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
D. E. Shaw & Co. Inc. Raises Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com UK
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Deutsche Bank AG - Defense World
Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Regenxbio Inc 주식 (RGNX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
자본화:
|
볼륨(24시간):